SCHEMBL6637776

SCHEMBL6637776

NC(=O)C1CCCC(CNC(=O)c2ccccc2)C1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.52
▸ CTSL P07711 2/20 0.51
▸ CTSB P07858 2/20 0.51
▸ CTSK P43235 2/20 0.51
▸ HDAC3 O15379 2/20 0.49
▸ HPGD P15428 1/20 0.49
▸ HDAC6 Q9UBN7 3/20 0.47
▸ HDAC4 P56524 1/20 0.47
▸ HDAC1 Q13547 1/20 0.47
▸ HDAC7 Q8WUI4 1/20 0.47
▸ HDAC2 Q92769 1/20 0.47
▸ HDAC10 Q969S8 1/20 0.47
▸ HDAC11 Q96DB2 1/20 0.47
▸ HDAC8 Q9BY41 1/20 0.47
▸ HDAC9 Q9UKV0 1/20 0.47
▸ HDAC5 Q9UQL6 1/20 0.47
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ CA2 P00918 1/20 0.47
▸ MLYCD O95822 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6640024 0.92 HDAC3 (0.55) SMN1; SMN2CTSLCTSBCTSKHDAC3
SCHEMBL6641152 0.84 HDAC1 (0.67) SMN1; SMN2CTSLCTSBCTSKHDAC3
SCHEMBL8393362 0.84 SMN1; SMN2 (0.68) SMN1; SMN2CTSLCTSBCTSKHDAC3
SCHEMBL6642407 0.83 SMN1; SMN2 (0.54) SMN1; SMN2CTSLCTSBCTSKHDAC3
SCHEMBL6637781 0.83 SMN1; SMN2 (0.54) SMN1; SMN2CTSLCTSBCTSKHDAC3
SCHEMBL21450578 0.82 SMN1; SMN2 (0.63) SMN1; SMN2CTSLCTSBCTSKHDAC3
SCHEMBL8391563 0.81 SMN1; SMN2 (0.73) SMN1; SMN2CTSLCTSBCTSKHDAC3
SCHEMBL28765695 0.79 CYP2D6 (0.53) CTSLCTSBCTSKHPGDMEN1
SCHEMBL25123079 0.79 SMN1; SMN2 (0.76) SMN1; SMN2CTSLCTSBCTSKHDAC3
SCHEMBL4522241 0.79 SMN1; SMN2 (0.76) SMN1; SMN2CTSLCTSBCTSKHDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1250340-B1 METHODS AND COMPOUNDS FOR INHIBITING MRP1 LILLY CO ELI (US) 2004-11-17 — — EP disclosed
US-20040176405-A1 Methods and compounds for inhibitting MRP1 KROIN JULIAN (US) 2004-09-09 — — US disclosed
EP-1250340-A1 METHODS AND COMPOUNDS FOR INHIBITING MRP1 ELI LILLY AND COMPANY (US) 2002-10-23 — — EP disclosed
WO-2001046199-A1 METHODS AND COMPOUNDS FOR INHIBITING MRP1 ELI LILLY AND COMPANY (US) 2001-06-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176405-A1 Methods and compounds for inhibitting MRP1 ABCC1, ABCB11, ABCB1 SMN1; SMN2 4263/4885CTSL 1603/4885CTSB 974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback